Change in bone mineral density for females using GnRH agonists

Effects of GnRH agonist on bone density in females with endometriosis and pelvic pain. Females with endometriosis and pelvic pain were treated with the GnRH agonist leuprolide depot for 52 weeks. Group A received GnRH agonist plus placebo pills. Group B received GnRH agonist plus norethindrone acetate 5 mg daily. Group C received GnRH agonist and norethindrone acetate 5 mg and conjugated equine estrogens 0.625 mg daily, and group D received GnRH agonist and norethindrone acetate 5 mg and conjugated equine estrogens 1.25 mg daily. No significant bone density loss occurred in the groups which received the GnRH agonist plus low dose steroid add-back.